Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

NCT00864760
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 4 Interventional

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159679
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Adolescent Fibromyalgia Study

NCT01020474
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, pregabalin (Lyrica)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
30
States / cities
Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

NCT01743651
View directory record Official record
Conditions
Spasticity, Multiple Sclerosis
Interventions
arbaclofen, baclofen, Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Cullman, Alabama • Long Beach, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 1:57 PM EDT
Withdrawn Phase 4 Interventional

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

NCT01042574
View directory record Official record
Conditions
Hypertension, Intracranial Hemorrhage, Subarachnoid Hemorrhage
Interventions
Clevidipine butyrate
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Does Reducing Spasticity Permit an Increase in Strength?

NCT00255073
View directory record Official record
Conditions
Spastic Diplegic Cerebral Palsy
Interventions
baclofen
Drug
Lead sponsor
University of Southern California
Other
Eligibility
5 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
BMS-954561, Pregabalin, Placebo matching BMS-954561, Placebo matching Pregabalin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 26, 2026, 1:57 PM EDT
Completed No phase listed Observational

Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study

NCT04771741
View directory record Official record
Conditions
Bunion of Unspecified Foot, Bunionette of Unspecified Foot, Hammertoe, Ankle Fractures, Achilles Tendon Surgery
Interventions
Acetominophen, Toradol, Meloxicam, Cyclobenzaprine, Lyrica
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 26, 2026, 1:57 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

NCT06905054
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Interventions
Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

NCT04256603
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Gabapentin, No gabapentin
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 26, 2026, 1:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Response to Fenofibrate

NCT01023750
View directory record Official record
Conditions
Hypertriglyceridemia, Insulin Resistance
Interventions
Fenofibrate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Cannabis Dependence

NCT00974376
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
Interventions
gabapentin 1200mg/day, Placebo, Manual-guided behavioral counseling
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 26, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management

NCT02605187
View directory record Official record
Conditions
Postoperative Pain
Interventions
No choice given, Choice given, Ibuprofen, Acetaminophen, Gabapentin, Morphine (low), Morphine (med), Morphine (high)
Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 26, 2026, 1:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy

NCT03625011
View directory record Official record
Conditions
Tonsillitis, Tonsillectomy
Interventions
Gabapentin
Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)

NCT00961116
View directory record Official record
Conditions
Healthy
Interventions
Fenofibric Acid (Fibricor™) 105 mg Tablet, Fenofibrate (Tricor®) 145 mg Tablet
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Oct 26, 2026, 1:57 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Pregabalin for Central Sensitization in TKA

NCT05460871
View directory record Official record
Conditions
Osteo Arthritis Knee, Central Nervous System Sensitization
Interventions
Pregabalin 75mg
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 26, 2026, 1:57 PM EDT
Terminated Phase 1 Interventional

FT516 in Subjects With Advanced Hematologic Malignancies

NCT04023071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, B-cell Lymphoma
Interventions
FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bonafide Sleep Supplement for Menopausal Women With Impaired Sleep

NCT07839299
View directory record Official record
Conditions
Sleep Disturbances
Interventions
S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 4 Interventional

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039
View directory record Official record
Conditions
Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions
colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
30 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 26, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Results available

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

NCT04114357
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetylated and Butyrylated High Amylose Maize Starch
Drug
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 26, 2026, 1:57 PM EDT